KRAS G12C-mutant non-small-cell lung cancer

What changed: KRAS G12C-mutant non-small-cell lung cancer

Cancer page →

Every dated change on the records linked to KRAS G12C-mutant non-small-cell lung cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Approval3Regulatory2Trial result4Milestone6This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordKRAS G12C-mutant non-small-cell lung cancer
Facts on this page last checked
When this page itself was last checked or edited.

2026 · 1

2026Trial resultKrascendo 1
Krascendo 1 reported
Superior PFS and OS vs approved G12C inhibitors (topline, July 2026).

2024 · 3

2023 · 1

2023MilestoneCodeBreaK 200
CodeBreaK 200: sotorasib beats docetaxel on progression-free but not overall survival
A milestone in how this cancer is treated.

December 2022 · 1

2022-12-12RegulatoryAdagrasib
Adagrasib: approval (US)
Accelerated approval, KRAS G12C NSCLC after ≥1 therapy

2022 · 3

May 2021 · 1

2021-05-28RegulatorySotorasib
Sotorasib: approval (US)
Accelerated approval, KRAS G12C NSCLC after ≥1 therapy: first KRAS inhibitor

2021 · 2

2016 · 1

2016Trial resultKEYNOTE-024 & KEYNOTE-189
KEYNOTE-024 & KEYNOTE-189 reported
5-year OS 31.

2013 · 1

2013MilestoneKevan M. Shokat
Ostrem and Shokat trap mutant G12C cysteine in the switch-II pocket
A milestone in how this cancer is treated.

1982 · 1

1982MilestoneKRAS
KRAS identified as a human oncogene in lung cancer cell lines
A milestone in how this cancer is treated.